Fluidised bed and spouted bed processes by Glatt offer manufacturers almost unlimited possibilities in terms of optimised particle design and the functionalisation of ingredients.
Glatt’s photovoltaic plant in Weimar is equipped with 252 solar modules and is used entirely for the company’s own needs.
In everyday life, environmental protection and the economical use of resources are important maxims of the company, the company emphasizes in its press release.
The desired end product properties can make a significant difference when choosing between spray drying or spray granulation.
Glatt Ingenieurtechnik was commissioned with the planning of the process engineering systems including media supply, control and automation of the process units as well as for the safety engineering.
Discover our expertise in fluid bed, spouted bed, and powder synthesis processes on our new focus webpage.
To celebrate the 25th anniversary, the family of the employees and some colleagues from the various Glatt sites were invited. The day was to be something special and memorable for the guests. That’s why there was not only something to see – people could also get active and make something themselves.
In the welcoming speeches, it became clear that the 350-strong workforce of GIT has every reason to be proud: “Today, GIT is a modern company,” said Dr. Reinhard Böber. “Plants from Weimar can be found all over the world – in Europe from Norway to Italy, as well as in South Africa, the USA or in Asia.”
Careful and comprehensive planning in advance of a cleanroom project is essential, regardless of whether the project is a conversion or a new build. Before the start of any cleanroom assembly, i.e. pharmaceutical interior construction, all structural measures must be as completely finished as possible. This means that the shell should be finished and the construction site completely clean. This is the only way to ensure that no particles from the surfaces of the building structure are carried over into the cleanroom to be built.
Drug formulation is a fine art and a matter for specialists. Even though many pharmaceutical companies like to take the path of least resistance when launching a drug on the market and, for the sake of simplicity, press the active ingredient into a tablet with a few excipients. But at the latest when the topic of life cycle management comes up, good advice is expensive, and that’s when Glatt Pharmaceuticals comes into play.
